FY2026 Earnings Forecast for SLDB Issued By William Blair

Solid Biosciences Inc. (NASDAQ:SLDB) – Investment analysts at William Blair issued their FY2026 earnings estimates for shares of Solid Biosciences in a note issued to investors on Friday, March 7th. William Blair analyst S. Corwin forecasts that the company will earn ($2.76) per share for the year. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

Several other equities analysts also recently commented on SLDB. Chardan Capital reiterated a “buy” rating and issued a $16.00 price objective on shares of Solid Biosciences in a research note on Friday. Truist Financial initiated coverage on Solid Biosciences in a research note on Wednesday, January 8th. They issued a “buy” rating and a $16.00 price objective on the stock. JMP Securities initiated coverage on shares of Solid Biosciences in a report on Tuesday, December 10th. They set an “outperform” rating and a $15.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on shares of Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Finally, Citizens Jmp raised shares of Solid Biosciences to a “strong-buy” rating in a report on Tuesday, December 10th. Nine equities research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $15.40.

Solid Biosciences Stock Down 1.5 %

Shares of NASDAQ SLDB opened at $5.42 on Monday. Solid Biosciences has a twelve month low of $2.88 and a twelve month high of $15.05. The stock’s 50 day moving average price is $4.07 and its 200-day moving average price is $5.56. The company has a market capitalization of $413.65 million, a PE ratio of -1.78 and a beta of 1.98.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vestal Point Capital LP raised its position in shares of Solid Biosciences by 1.8% during the 4th quarter. Vestal Point Capital LP now owns 2,850,000 shares of the company’s stock valued at $11,400,000 after buying an additional 50,000 shares in the last quarter. Redmile Group LLC purchased a new stake in shares of Solid Biosciences during the 4th quarter valued at about $2,461,000. D. E. Shaw & Co. Inc. purchased a new stake in shares of Solid Biosciences during the 4th quarter valued at about $208,000. Corton Capital Inc. purchased a new stake in shares of Solid Biosciences during the 4th quarter valued at about $41,000. Finally, Cubist Systematic Strategies LLC raised its position in shares of Solid Biosciences by 479.4% during the 4th quarter. Cubist Systematic Strategies LLC now owns 65,613 shares of the company’s stock valued at $262,000 after buying an additional 54,288 shares in the last quarter. Institutional investors own 81.46% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.